SAN MARINO, Calif.--(BUSINESS WIRE)--The first patient has now been enrolled into the Phase 1 clinical trial sponsored by Viral Genetics’ (OTC Pink: VRAL) and supported by a donation from Scott and White Foundation. The trial will study Metabolic Disruption Technology (MDT) compounds in combination with an existing cancer therapy to treat drug-resistant ovarian cancer. A total of up to 24 patients will receive combination treatment of hydroxychloroquine and sorafenib (marketed as Nexavar™) under primary investigator, Tyler Curiel, M.D., MPH, a medical oncologist affiliated with The Cancer Therapy and Research Center (CTRC) of The University of Texas Health Science Center at San Antonio. This clinical trial is the first sponsored by Viral Genetics based on the licensed research of Dr. M. Karen Newell-Rogers, the Company’s Chief Scientist, and represents a milestone in the transition of the Company from preclinical- to clinical-stage. Patient enrollment is also expected to commence at Scott and White Hospital as soon as internal review procedures there are finalized.
